CD274 and esophageal squamous cell carcinoma: The phase III CHECKMATE 648 trial randomized 970 untreated ESCC patients with advanced disease to receive nivolumab plus chemotherapy (cisplatin and 5-fluorouracil; nivolumab and ipilimumab; or chemotherapy alone, independently of the PD-L1 expression).